Most Read Articles
6 days ago
Older women with longer endogenous oestrogen exposure and hormone therapy use are at much higher odds of having favourable cognitive status in late life, a recent study suggests.
4 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Elvira Manzano, 5 days ago
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
Jairia Dela Cruz, 2 days ago
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.

Orvepitant delivers sustained improvements in chronic refractory cough

18 Sep 2019

Treatment with the neurokinin-1 receptor antagonist orvepitant appears to be safe in patients with chronic refractory cough, yielding sustained improvements in cough frequency and severity, according to the results of the phase II VOLCANO-1 trial.

Thirteen patients with daytime cough frequency of >3 to <250 coughs/hour received orvepitant 30 mg once daily for 4 weeks. Objective cough frequency was measured over 24 hours at several time points: baseline and weeks 1, 4, and 8.

The primary outcome was change in daytime cough frequency at week 4. Secondary outcomes included cough severity score on visual analogue scale (VAS), global ratings of change for cough frequency and severity, and Cough-specific Quality of Life Questionnaire score.

Mean objective daytime cough frequency at baseline was 71.4/hour. This improved by 26 percent at week 4, translating to a decrease of 18.9 coughs/hour (95 percent CI, 9.6–28.3; p<0.001).

The improvement was already evident during the first week of treatment (reduction from baseline of 38 percent or 27.0 coughs/hour, 11.4–42.7; p=0.001) and sustained after drug discontinuation through week 8 (reduction of 29 percent or 20.4 coughs/hour, 3.2–37.5; p=0.020). There were significant, parallel improvements seen in severity VAS and quality of life scores.

These findings show that orvepitant merits further clinical investigation, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Older women with longer endogenous oestrogen exposure and hormone therapy use are at much higher odds of having favourable cognitive status in late life, a recent study suggests.
4 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Elvira Manzano, 5 days ago
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
Jairia Dela Cruz, 2 days ago
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.